ACE and Stroke: The results of three recent clinical studies of telmisartan, including the Prevention Regimen For Effectively avoiding Second Strokes (PRoFESS) [62], Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) [63], and the Telmisartan Randomized Assessment Study in ACE-intolerant Subjects with Cardiovascular Disease (TRANSCEND) [64] have suggested a modest neurovascular protective effect of telmisartan against stroke events.